A Phase I Study to Assess the Safety, Tolerability and Preliminary Efficacy of Human Allogeneic Induced Pluripotent Stem Cells (iPSCs) -Derived Motor Neuron Progenitor Cells (XS228CN) in Subjects With Amyotrophic Lateral Sclerosis
XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd. is advancing a Phase I clinical trial for XS228CN, a novel therapy utilizing iPSC-derived motor neuron progenitor cells aimed at treating ALS. The ALS market is characterized by a high unmet need, with limited effective therapies currently available. The successful demonstration of safety and preliminary efficacy could position XS228CN as a significant player in the ALS treatment landscape, potentially attracting partnerships or acquisition interest from larger biopharmaceutical companies. Given the trial's focus on a debilitating and progressive disease, positive outcomes could enhance the company's valuation and market presence.
Indication: Amyotrophic Lateral Sclerosis (ALS)
Modality: small molecule
Target: Human Allogeneic Induced Pluripotent Stem Cells (iPSCs) -Derived Motor Neuron Progenitor Cells (XS228CN) targeting motor neuron degeneration in Amyotrophic Lateral Sclerosis (ALS).
Sponsor: XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 10, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Human Allogeneic Induced Pluripotent Stem Cells (iPSCs) -Derived Motor Neuron Progenitor Cells (XS228CN) targeting motor neuron degeneration in Amyotrophic Lateral Sclerosis (ALS).
View original source fields
Condition raw: Amyotrophic Lateral Sclerosis (ALS)
Condition normalized: Amyotrophic Lateral Sclerosis (ALS)
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Human Allogeneic Induced Pluripotent Stem Cells (iPSCs) -Derived Motor Neuron Progenitor Cells (XS228CN) targeting motor neuron degeneration in Amyotrophic Lateral Sclerosis (ALS).
Target normalized: Human Allogeneic Induced Pluripotent Stem Cells (iPSCs) -Derived Motor Neuron Progenitor Cells (XS228CN) targeting motor neuron degeneration in Amyotrophic Lateral Sclerosis (ALS).